How plan sponsors can use biosimilars to support employee health, reduce drug costs
Despite the safety and efficacy of biosimilars — and the potential cost savings they offer — uptake among private payers has been low historically and is only starting to…
- By: Kelsey Rolfe
- January 22, 2024 January 22, 2024
- 07:54